NewAmsterdam Pharma Company NV has announced a new compensation agreement for Dr. John Kastelein, the company's Chief Scientific Officer and director. Effective from July 1, 2025, this amended and restated Employment Agreement replaces the previous one dated November 18, 2022. Under the new terms, if Dr. Kastelein's employment is terminated without cause, he will receive a severance package including 12 months of his base salary, any earned or payable bonuses, and a prorated bonus for the year of termination. Additionally, should his termination occur related to a change in control, his time-based stock options and equity awards will be accelerated, making them fully exercisable or nonforfeitable, with an extended exercise period for certain options. These changes reflect significant enhancements to Dr. Kastelein's compensation and benefits package.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.